SOUTH AFRICA

UltraChoice® 7

Reg. No.: G2804 (Act 36/1947)

  • For animal use only.
Expand All
  • UltraChoice® 7 consist of killed, standardised cultures of Cl. chauvoei, Cl. septicum, Cl. novyi, Cl. sordellii, Cl. perfringens Type C & D. Immunity against Cl. perfringens Type B is provided by the beta toxoid of Type C and the epsilon toxoid of Type D, with a special, water-soluble adjuvant (Stimugen™).

  • UltraChoice® 7 is used for vaccination of healthy cattle and sheep as an aid in preventing black quarter caused by Clostridium chauvoei, malignant oedema caused by Cl. septicum; black disease caused by Cl. novyi; gas-gangrene caused by Cl. sordellii; and enterotoxemia and enteritis caused by Cl. perfringens Type B, C and D.

    • Use only as directed:
    • Vaccination of healthy cattle and sheep is recommended. UltraChoice® 7 should be administered aseptically subcutaneously.

     

    • Cattle:
    • Primary Vaccination: Administer a single 2 ml dose to healthy cattle, followed by a second dose of UltraChoice® 7, 4 - 6 weeks later.
    • Revaccination: Annual revaccination with a single dose of UltraChoice® 7 in cattle and sheep is recommended.

     

    • Sheep:
    • Primary Vaccination: Administer a single 1 ml dose to healthy sheep, followed by a second dose of UltraChoice® 7, 4 - 6 weeks later.
    • Revaccination: Annual revaccination with a single dose of UltraChoice® 7 in cattle and sheep is recommended.
    • Do not vaccinate within 21 days before slaughter.
    • Keep out of reach of children, uninformed persons and animals.
    • As with most vaccines, anaphylaxis may occur after use. Initial antidote of adrenalin is recommended and should be followed with appropriate supportive therapy.
    • Transient local swelling at injection site may occur following vaccination.
    • This product has been shown to be efficacious in healthy animals. A protective immune response may not be elicited if animals are incubating an infectious disease, are malnourished or parasitized, are stressed due to shipment or environmental conditions, are otherwise immunocompromised, or the vaccine is not administered in accordance with label directions.
    • Milk production may be reduced in cows for up to six days following vaccination, thereafter milk production will return to normal.
    • Although this vaccine has been tested extensively under a large variety of conditions failure thereof may ensue as a result of a wide range of reasons. If this is suspected, seek veterinary advice and notify the registration holder.
    • Store between 2º C and 7º C. Do not freeze. Prolonged exposure to higher temperatures and/or direct sunlight may adversely affect potency.
    • 100 ml vial (50 doses for cattle or 100 doses for sheep)

DISCLAIMER: ALTHOUGH GREAT CARE HAS BEEN TAKEN IN THE COMPILATION OF THIS DOCUMENT, READERS ARE REQUESTED TO REFER TO THE PACKAGE INSERT FOR COMPLETE DETAILS BEFORE USING THE SPECIFIC PRODUCT.

Ordering Products

Fax no. for Orders:
+27 21 427 6442
 
Email address for Orders:
ZoetisOrders@zoetis.com
 
Physical Address:
Zoetis South Africa (Pty) Ltd.
Co. Reg. No.: 2012/001825/07
6th Floor, North Wing, 90 Rivonia Road, Sandton, 2196.
 
Tel:
+27 11 245 3300 or 0860 ZOETIS (0860 963847)

Terms of sale

Postal Address

Zoetis South Africa (Pty) Ltd
PostNet Suite 53
Private Bag 9976
Sandton
2146